Theodorou joins Defence board

Defence Therapeutics Inc. has announced that Dr. Elias Theodorou has joined its board of directors, effective immediately. Dr. Theodorou is a molecular biologist with over 25 years of experience in cancer research, stem cell differentiation, and gene delivery.

He is the Chief Scientific Officer and co-founder of Protos Biologics Inc., where he has developed innovative DNA delivery systems. Previously, he served as the Director of Research at WBC Biosciences LLC, where he co-invented a method to modify innate immune cells for enhanced anticancer properties.

Dr. Theodorou has extensive experience in the healthcare sector, having held leadership roles at ATUM Inc. and Metagenomix Inc., significantly advancing molecular biology tools and inventing novel methods for drug screening.

He earned his PhD from Yale University, focusing on identifying novel drivers of neural differentiation. Dr. Theodorou has also authored numerous publications and holds patents related to gene therapy and protein engineering.

Sébastien Plouffe, President, CEO and Founder of Defence Therapeutics, commented: “With his vast experience in gene and payload delivery, we are grateful to welcome Dr. Elias Theodorou to our board of directors.”

They are grateful to have Dr. Theodorou on board due to his extensive knowledge, involvement and leadership roles with successful US biotech companies.

“I believe the Accum technology has great potential in the ADCs and radiopharmaceuticals applications. I am excited to join Defence Therapeutics on the board of directors, to bring my knowledge and guidance to the Company’s development, as well as to be part of its success”, stated Dr. Theodorou.

The company has granted 100,000 incentive stock options to Dr. Theodorou in accordance with the terms and conditions of Defence’s stock option plan. Each stock option vests immediately and is exercisable at a price of 60 cents per share for a period of three years from the grant date.

The Company would also like to announce that Mr. Arnab De has been appointed CFO and Corporate Secretary and is stepping down from the board of directors, effective immediately, in replacement of Mr. Joseph Meagher (former CFO) and Miss Carrie Cesarone (former Corporate Secretary).

Defence Therapeutics thanks Mr. Meagher and Miss Cesarone for their valuable contributions. Defence’s current board of directors are represented by five board members: Mr. Sébastien Plouffe, Dr. Sarkis Meterissian, Dr. Philippe Lefrançois, Dr. Svetlana Selivanova and Dr. Elias Theodorou.

It is expected that Dr. Theodorou’s experience in molecular biology will be valuable to Defence Therapeutics. The company’s focus on antibiotic use is expected to benefit from his expertise.

Defence Therapeutics now has a mix of experienced professionals from the biotech industry.

In the healthcare sector, experience and knowledge are essential for success.

More information on Defence Therapeutics can be found on the US Securities and Exchange Commission website. The company’s leadership team is well-equipped to handle the challenges of the biotech industry.

Dr. Theodorou’s background in cancer research and gene delivery will likely be beneficial to Defence Therapeutics.